Need professional-grade analysis? Visit stockanalysis.com
$323.54M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Northwest Biotherapeutics Inc (NWBO) Price Performance
Northwest Biotherapeutics Inc (NWBO) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $0.21, up 3.65% from the previous close.
Over the past year, NWBO has traded between a low of $0.19 and a high of $0.44. The stock has lost 12.5% over this period. It is currently 52.3% below its 52-week high.
Northwest Biotherapeutics Inc has a market capitalization of $323.54M.
About Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $937,000
- EBITDA
- $-63,136,000
- Profit Margin
- -6062.08%
- EPS (TTM)
- -0.06
- Book Value
- -0.07
Technical Indicators
- 52 Week High
- $0.48
- 52 Week Low
- $0.17
- 50 Day MA
- $0.26
- 200 Day MA
- $0.25
- Beta
- -0.83
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- 345.30
- Price/Book
- -2.92
- Enterprise Value
- $414.05M